Tuesday, July 25, 2017 5:00:22 PM
I am still a long holder, and although I am also quite disappointed in the past years developments [price wise] I am compelled to point out that you all seem to be up in arms, in regard to one or two negative posters. Of which you have no credentials of their validity or motive.
Although one has brought up a few compelling points, [share price decline, lack of news on Phase 1 final data, delayed start of Phase 2 her2nue in breast cancer from mayo]
I feel that I must interject here, that you should not rely on posters on this board for [real news] but instead should rely more on the fact that TPIV has progressed significantly over the past year 18 months. And now is a viable company on the NASDAQ.
Low float, very little debt, promising product and cash in the bank.
Although discouraging in the stock price, and some execution of trial timelines. One must remember that the FDA has granted both Orphan status and fast track to one of TPIV's vaccine candidate's, that the DOD has ponied up 17 million, after looking at data.
They have attracted the likes of AZN and Sloane Kettering, and others once again after having vetted the data to this point.
I am also frustrated at the lake of execution, on some fronts, but Cancer is not an easy task, and it is better to go slow, than to move quickly and have problems arise down the road. [Phase 111]
Who's word should be taken anonymous posters, or MAYO [Keith Knutson, Edith Perez], DOD, FDA AZN, Sloane Kettering and others.
Although I am from Canada I am now thinking strongly of attending the Annual meeting, to ask some tough questions, if my schedule permits.
Wilfred Jefferies of UBC was one of the first scientists in the development of TAP, and the science way back in 1991 seemed sound. Since then the company has morphed into what may be a substantial player in the Immunology field.
Do we have the right management in place, who knows, but the science has been vetted by many individuals smarter than us. The Bio-Tech sector is boom or bust but to this point seems to have strong validation.
TPIV has various fronts on which to execute, Merger, Buyout two very real possibilities [if science holds through initial Phase 11]
It is all up to the science at this point, and none of us will know the outcome until too late, bust or boom. I for one will stay put and put my faith in the Mayo, DOD and AZN and others at this point. Whatever the outcome we will be the last to know.
So if you feel that their has not been enough validation to date, than you have the option to sell, but I am going to wait it out and let the science prove out, one way or the other.
If their science is as good as it seems, than it would be plausible that BP and others may be trying to scare or inject doubt into shareholders. Manipulation is just part of investing. If TPIV has the goods, than Roche that markets Herceptin [6/7 Billion per year] and others would have just cause, to make it difficult to execute TPIV's plans.
Remember they have more than one path moving forward, multiple cancers addressed, Infectious Disease and their newly in-house Polystart which may have many significant applications for generating revenue.
All in all, at this point their still seem to be many more positives, than negatives with TPIV at this point in time, the Annual will give lots of insight moving forward.
Either way with all the big investors and lack of liquidity, at this point we are going to be the last to know, and last to get out, unless you deem it in ones best interest to do so at these levels.
I myself still think that the science has merit, and the fundamentals seem to be unchanged to this point [negatively]
I am a buyer at these levels, for me it is more than the money but the fact that the science may drastically change the lives of millions.
Best of luck to all, TPIV will either bust or boom, but even the management will not be able to curtail it's success if the science is sound. If sound they will be bought out and the price tag will be monumental.
BLU [AKA SHAWN]
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM